Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT04176718 is registered in ClinicalTrials.gov with Andrew Yee, MD as lead sponsor.

NCT NCT04176718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Lead sponsor
Andrew Yee, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 18, 2020
Completion date
May 31, 2028
Enrollment
44 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse, refractory multiple myeloma, relapse